Haleon PLC (H6D0) Stock Price & Analysis
H6D0 Stock Chart & Stats
- Day’s Range
- EUR 3.87 - EUR 3.93
- 52-Week Range
- EUR 3.72 - EUR 4.78
- Previous Close
- EUR 3.83
- Volume
- 16.56K
- Average Volume (3M)
- 29.68K
- Market Cap
- EUR 33.59B
- Enterprise Value
- EUR 38.50B
- Total Cash (Recent Filing)
- EUR 826.00M
- Total Debt (Recent Filing)
- EUR 8.25B
- Price to Earnings (P/E)
- 17.6
- Beta
- 0.16
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.39%
Bulls Say, Bears Say
Bulls Say
Durable Cash Generation
Consistent operating and free cash flow indicates that Haleon’s earnings are supported by cash rather than accounting effects. This provides capacity to fund brand investment, productivity programs, debt reduction and shareholder distributions through varied market conditions.
Margin Expansion And Productivity
Recent margin expansion combined with structural supply-chain and operating-model savings can strengthen profitability beyond simple price increases. The savings pipeline should give management flexibility to reinvest in marketing and innovation while absorbing selected cost pressures.
Oral-care Brand Strength
Strong oral-care growth supports the durability of Haleon’s branded portfolio because toothpaste and mouthwash are recurring-use products. Continued clinical innovation and penetration gains can reinforce consumer loyalty, shelf presence and repeat purchasing over time.
Bears Say
Leverage Remains Elevated
Although debt declined in 2025, leverage remains higher than earlier years, leaving less balance-sheet flexibility than Haleon previously had. This can constrain capital allocation and make the company more sensitive to weaker operating performance or prolonged cost pressure.
Respiratory Category Weakness
Persistent weakness in respiratory and cough-and-cold products can weigh on portfolio growth because these categories are meaningful parts of Haleon’s OTC offering. Continued decline or delayed recovery would make guidance more dependent on other brands and regions.
Regional And Pricing Pressure
Regional softness and negative pricing in parts of the international portfolio can dilute consolidated growth even when North America and selected emerging markets perform well. Inflationary pressures and contract roll-offs may also challenge margins and require additional execution.
Haleon PLC News
H6D0 FAQ
What was Haleon PLC’s price range in the past 12 months?
What is Haleon PLC’s market cap?
When is Haleon PLC’s upcoming earnings report date?
How were Haleon PLC’s earnings last quarter?
Is Haleon PLC overvalued?
Does Haleon PLC pay dividends?
What is Haleon PLC’s EPS estimate?
How many shares outstanding does Haleon PLC have?
What happened to Haleon PLC’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Haleon PLC?
What is the TipRanks Smart Score and how is it calculated?
Haleon PLC Stock Smart Score
Company Description
Haleon PLC
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially named DRVW 2022 plc before rebranding to Haleon plc in February 2022. Its corporate headquarters are located in Brentford, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Brian James McNamara
- Employees
- 24,535
- Website
- www.haleon.com
- Address
- The Heights, Weybridge, SU, KT13 0NY, GB
Haleon PLC (H6D0) Earnings & Revenues
H6D0 Earnings Call
Earnings Call SentimentPositive
The call presented a constructive operational and financial picture: solid organic growth (3.1% in the quarter), strong margin expansion (gross margin +140 bps, operating margin +120 bps) and double‑digit EPS growth, supported by supply‑chain productivity, digital/e‑commerce momentum and targeted regional execution (China, LatAm, India). However, notable near‑term headwinds remain in respiratory/cold & flu, Europe and specific Middle East markets, plus some pricing pressure in APAC from hospital channel activity. Management maintained FY guidance (3%–5%) and expects a stronger second half, suggesting confidence in execution despite the regional and category uncertainties.
View all DE:H6D0 earnings summariesH6D0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |